Jefferies 2012 Global Healthcare Conference

1

NASDAQ: CYTXJefferies Global Healthcare Conference

June 5, 2012

i. Technology & Investment Summaryii. Cardiovascular Disease Pipelineiii. Breast Reconstruction & Commercial Businessiv. Business & Economics

Safe Harbor Statement

2

This presentation may contain certain ‘forward-looking statements’. All

statements, other than statements of historical fact, that address activities, events

or developments that we intend, expect, project, believe or anticipate will or

may occur in the future are forward-looking statements. Such statements are

based upon certain assumptions and assessments made by our management in

light of their experience and their perception of historical trends, current

conditions, expected future developments and other factors they believe to be

appropriate.

The forward-looking statements included in this presentation are also subject to a

number of material risks and uncertainties. We caution investors not to place

undue reliance on the forward-looking statements contained in this presentation.

We would advise reading our annual report filed with the United States Securities

and Exchange Commission on Form 10-K for a more detailed description of these

risks.

3


Cytori Investment Summary

4

Overview Cell therapies sourced from point-of-care device

Cardiovascular disease & soft tissue defects (i.e. breast recon)

Device approved in Europe; starting U.S. clinical trials

Valuable Pipeline Seeking chronic ischemia approval in Europe

Approved to begin chronic ischemia trial in U.S

EU heart attack pivotal trial

Commercial Business Bridge to Higher Value Markets Build for profitable growth

Seeking breast reconstruction reimbursement; path to profitability

Enter/grow in emerging markets

Razor-razorblade model: low COGS, high margins

Patent protection into 2030s and beyond

Cell Therapy: Fourth Tenet of Medicine

5

Cell Therapy Platform: Innovative & Affordable

6

Cardiovascular Disease

Celution® System:

point-of-care device

Adipose-derived

regenerative cells (ADRCs)

Fat (adipose) tissue

from minor liposuction

Cell Therapy Platform: Richest Cell Source

7

Number of Cells (millions) per 100 mL of tissue (1/2 cup)

0

0.25

0.5

Multipotent Cells in AdiposeMultipotent Cells in BM

0

15

30

45

Total Nucleated Cells in Adipose

Implication: Real-time access to a patient’s own regenerative cells is possible(No lengthy cell culture or manufacturing involved)

Cell Therapy Platform: Multiple Therapies

Approved in Europe

Clinically validated for high physician and

patient satisfaction

Seeking reimbursement

Completed two human trials

Sustained functional benefit at 18 months

Pivotal heart attack trial in Europe underway

US chronic heart disease trial approved to begin

Approved in Europe for certain chronic wounds

Independent studies investigating several soft tissue applications such as burns, radiation injury, diabetic foot ulcers and others

Demand by researchers for access to cells

Preclinical & clinical studies exploring new indications:

Acute renal failure Liver disease Stress urinary incontinence Ischemic stroke

Cardiovascular Disease

Soft Tissue Repair & Wounds

Discovery of New Applications

Breast Reconstruction

9


Cardiovascular Disease: Overview

10

I. Seeking European approval in 2012 in no-option chronic

myocardial ischemia patients

II. Initiating U.S. chronic myocardial ischemia trial 1H 2012;

The ATHENA Trial

III. Enrolling pivotal (approval) heart attack trial in Europe:

The ADVANCE Trial

Chronic Myocardial Ischemia (CMI)

11

Condition: Severe form of coronary artery disease, limits

mobility, results in chest pains from ischemic tissue

Disease Course: Multiple revascularization procedures

without improvement resulting in limited therapeutic options

Size of Market: Approx.120K to 250K diagnosed each year in

U.S.; subset of approx. 5.8 MM heart failure patients

ADRCs & Cell Therapy: Potential to revive living but stressed

heart tissue; keep patient off transplant list; overcome limits

of existing drugs, devices and surgical options

ADRCs for CMI: Targeted Delivery to Muscle

Direct injection into “hibernating” heart muscle

via catheter

ADRCs for CMI: Clinical Trial Outcomes

13

Soft Tissue RepairSoft Tissue Repair

Soft Tissue Repair

Change in Max Volume of Oxygen (MV02) from Baseline to 6 & 18 months

Baseline 6 Mos 18 Mos

Transplant List

20.0

18.0

16.0

14.0

19.0

15.5 15.3

16.6

17.117.2

ADRC’sStandard of Care

P<0.05 P<0.05

N = 27 pts

(6 placebo/21 treated)

ADRCs for CMI: Clinical Trial Outcomes

14

MVO2: significant change at 18 months• MVO2 correlates to improved survival

• MVO2 ≤ 14 = 47% 1 yr survival rate

METS: significant change at 18 months

Cytori procedure safe and feasible through 18-months

Lower cardiac mortality rate:• At avg. follow-up of 28 months:

- 2/6 placebo

- 1/21 treated

0% 10% 20% 30% 40%

Placebo

Treated

33%

5%

28 Month Mortality Rate

Acute Myocardial Infarction (AMI/Heart Attack)

15

Condition: Artery blockage inhibits blood flow to heart

muscle resulting in stunned ischemic tissue

Disease Course: Large attacks lead to heart failure if

ischemic tissue is not revascularized;

Size of Market: Approx.1 million heart attack patients

admitted to hospital each year

ADRCs & Cell Therapy: Potential to minimize heart damage;

additive to existing treatments; potential to reduce

healthcare costs & rehospitalizations linked to heart failure

ADRCs for AMI: Clinical Trial Outcomes

16

Potential new approach for treatment of heart attacks

Safe & efficacious

Higher serious adverse event rate in Controls

P < 0.05 for change from BL for ADRCs

P > 0.05 for change from BL for Placebo

ADRCs for AMI: Clinical Trial Outcomes

17

Lower abnormal ventricular beat rate

More significant Ventricular Arrhythmias in placebo

Higher frequency of recordings with Ventricular Premature Beats (VPB) in Controls

Higher #of VPBs per recording in placebo

Cytori Cardiac Cell Therapy: Next Steps

18

Approval decision for European CMI•Limited launch

•Patient registry •Build market access; top hospitals in Europe

Initiate ATHENA U.S. pilot trial for CMI•Multi-center, double-blind, 45 patients

•FDA approved design in Jan 2012

Accelerate enrollment in ADVANCE heart attack pivotal trial•30-35 sites to treat up to 360 patients

•20+ sites selected and committed

•2012 focus on getting sites online

19



Celution® approved in EU for breast reconstruction

Two completed clinical trials

Safe: Five-plus years follow-up

Favorable reimbursement environment

Limited options available to patients today

$43

$73

$126 $163Clinic

alPartner

Cells Fat

‘ADRC-Enriched Graft’

Soft Tissue Repair: RESTORE Procedure

Soft Tissue Repair: RESTORE Procedure

Pre-Reconstruction; Post radiation treatment & tumor resection

9-Mo Post-Reconstruction using RESTORE Procedure


Soft Tissue Repair

$73

$126

Post-Marketing Study Design

• Prospective 71 patient study

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

Patient

Satisfaction Physician

Satisfaction

6-Mo

12-Mo

Soft Tissue Repair: Trial Outcomes

Takeaways:

• High satisfaction & safety to support

reimbursement

• Improved breast contour at both six

and 12 months (blinded MRI)

• No local cancer recurrences or serious

adverse events

• Satisfactory results can be achieved in

one procedure for majority of patients

• Competitive approaches more costly:

lengthy hospital stays, repeat

procedures & increase overall burden

on healthcare system

23


Product Pricing

24

Low six figure ASP for

sale & installation

$2,000-$12,000 for per-

procedures cartridge

ASP dependent on

indications and formulation

60-80% Margin

Devices (Current) Devices

Next

Generation

Soft Tissue

Recon &

Aesthetics)

Cardiovascular Therapies Pipeline

Therapies

US: (5)

CELUTION DEVICE (‘484)

CELUTION DEVICE PLUS ADDITIVES (‘420)

STEMSOURCE DEVICE (‘115)

CELUTION DEVICE PLUS SENSORS FOR

CLINICALLY SAFE OUTPUT (‘670)

BEDSIDE COMPREHENSIVE

DEVICE (‘059)

JAPAN: (2)


CELUTION FOR CLINICALLY SAFE OUTPUT

(‘556)

KOREA: (3)




INDIA: (1)


AUSTRALIA: (1)



CHINA: (1)


US: (1)

CELUTION FUTURE

GENERATIONS (‘075)

INDIA: (1)

CELUTION FUTURE

GENERATIONS (‘529)

AUSTRALIA: (1)

CELUTION WITH

CENTRIFUGE OR

FILTER (‘937)

SINGAPORE: (1)

CELUTION & FUTURE

GENERATIONS

(‘683)

ISRAEL: (1)

CELUTION WITH

CENTRIFUGE OR

FILTER (‘800)

MEXICO: (1)

CELUTION FUTURE

GENERATIONS

US: (4)

CELUTION FOR

MIXING ADRCS PLUS

FAT (‘488)

CELUTION OR NEXT

GEN DEVICES FOR

SOFT TISSUE DEFECTS

(‘684)

ADRCS PLUS FAT

PLUS ADDITIVES

(‘795)

ADRCS PLUS FAT

(‘672)

JAPAN: (1)

CELUTION AND NEXT

GEN DEVICES FOR

MIXING ADRCS PLUS

FAT (‘041)

KOREA: (1)

ADRCS PLUS FAT

(‘041)

EUROPE: (2)

ADRCS FOR CARDIAC (‘382)

OPPOSED

DEVICE FOR RESTORING BLOOD FLOW

(‘575)

AUSTRALIA: (1)


SINGAPORE: (1)

ADRCS FOR RESTORING BLOOD

FLOW(‘590)

CHINA: (1)

ADRCS FOR RESTORING BLOOD FLOW

(‘104)

RUSSIA: (1)

CELUTION FOR RESTORING BLOOD FLOW

(‘924)

SOUTH AFRICA: (1)


MEXICO: (1)

CELUTION FOR RESTORING BLOOD FLOW

(‘775)

ISREAL: (1)


US: (2)

CELUTION FOR

BONE (‘043)

CELUTION OUTPUT

PLUS PROSTHETIC

FOR BONE

RELATED

DISORDERS (‘716)

EUROPE: (2)

CELUTION FOR

ACUTE

TUBULAR

NECROSIS (‘834)

ADRCS FOR

WOUND

HEALING (‘833)

JAPAN: (1)

ADRCS FOR

WOUND HEALING

(‘699)

INDIA: (1)

ADRCS FOR

WOUND HEALING

(‘580)

Protected into 2030s: 46 Patents WW; 75+ Pending

Financial Highlights

26

Cash and cash equivalents (3/31/12) $34.4

Accounts receivable 1.4

Long-term debt (GE Capital) 24.6

2011 Product sales $8.0

2011 Cost of sales 3.8

2011 Gross profit 4.1

2011 Net cash used in op. activities 35.3

2012 Revenue guidance >$9.0

2012 Research & Development Increase

2012 Sales & Marketing Reduce

2012 G&A Reduce

2012 Projected Quarterly Burn <$7 MM

Total shares outstanding (4/30/12) 58.7 MM

1. Move product development pipeline forward

• ATHENA in U.S. for CMI & ADVANCE in Europe for AMI

• European approval decision for no-option CMI in Europe

2. Get commercial business profitable in 12-18 months

• 20+% annual revenue growth until inflection point

• Focus on breast reconstruction reimbursement in UK

• Build market access for no-option CMI in Europe

• Expand regulatory approvals and indications

3. Execute on Corporate Milestones

• Development and commercialization partnerships (i.e. Astellas)

• Reduce total operating expenses & burn through G&A and S&M

reductions offset with increase in R&D

Creating Shareholder Value in 2012

Receive approval (IDE clearance) to begin ATHENA CMI trial

Celution® approval in additional countries (Russia May ’12, more to come)

Initiate ATHENA trial in U.S.

CE Mark for chronic myocardial ischemia

Breast reconstruction technology evaluation in UK

Strategic Partner(s)

Potential Near-Term Catalysts